课题基金 / 基金详情

The efficacy of anti-Aβoligomer antibody to the toxicity of Aβto neuronal cells

The efficacy of anti-Aβoligomer antibody to the toxicity of Aβto neuronal cells
抗Aβ寡聚体抗体对抗Aβ对神经元细胞毒性的功效
批准号:
21591524
负责人:
HAYASHI Yoshihito
金额:
$3.0万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2009
资助国家:
日本
项目状态:
已结题
起止时间:
2009 至 2011

项目摘要

项目成果

HAYASHI Yoshihito的其他基金

相似基金

相关文献

中文摘要
翻译
最常见的痴呆类型是阿尔茨海默病(AD)。AD的病因被认为是由淀粉样前体蛋白(APP)裂解而成的淀粉样β蛋白(Aβ)具有神经毒性,可诱导神经细胞死亡。近年来有研究发现可溶性寡聚体对突触有毒性作用,可导致认知功能下降。我们认为抗寡聚体抗体具有神经保护作用。本研究探讨了抗寡聚体抗体对Aβ毒性神经细胞的保护作用机制。我们研究了当Aβ自身聚集时,抗寡聚体抗体是否减少自由基形成的量。与对照溶液相比,自由基形成量减少。在培养液中加入抗寡聚体抗体和Aβ后,PC12细胞的存活率明显提高。结果发现,在含有抗寡聚体抗体的培养液中加入Aβ后,PC12细胞NMDA受体的数量发生了变化。我们没有证实抗寡聚体抗体对NMDA受体的作用是直接的还是间接的。我们认为这两个性质之间存在着某种联系。
英文摘要
The most popular type of dementia is Alzheimer's disease(AD). The cause of AD is thought that amyloid beta protein(Aβ) cleaved from amyloid precursor protein(APP) which is expressing on the neuronal cell membranes has neurotoxicity and induce neuronal cell death. Recently some researchers found the soluble oligomer form had toxicity to the synapses and induce cognitive decline. We thought that anti-oligomer antibody has neuroprotective effect. We investigated the mechanisms of neuroprotective effect of anti-oligomer antibody against neuronal cells from Aβtoxicity. We investigated whether or not anti-oligomer antibody reduce the amount of free radical formation when Aβaggregate themselves. The amount of free radical formation was reduced compared with control solution. The viability of PC12 cells was higher when culture medium was added anti-oligomer antibody with Aβ. We found some changes of amount of NMDA receptor in PC12 when added Aβto culture medium with anti-oligomer antibody. We did not confirm whether the effect of anti-oligomer antibody against NMDA receptor was direct or indirect effect. We thought that there are some relations between two properties.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An open label study to ascertain the effect of a traditional Japanese medicine, yokukansan, short-term treatment on the BPSD in patients with AD
一项开放标签研究,旨在确定日本传统药物 yokukansan 的短期治疗对 AD 患者 BPSD 的影响
DOI: --
发表时间: 2011
期刊:
影响因子: --
作者: [Hayashi Y, Ishida Y, Okahara K, Mitsuyama Y]
通讯作者: Mitsuyama Y
アルツハイマー型認知症の周辺症状(BPSD)に対する抑肝散の効果-日常診療下における検討:入院患者における部分集団解析-
抑肝散对阿尔茨海默病(BPSD)周围症状的影响 - 日常临床实践检查:住院患者的亚组分析 -
DOI: --
发表时间: 2010
期刊: Geriatric Medicine(老年医学)
影响因子: --
作者: [林要人, 石田康, 井上輝彦, 宇田川充隆, 竹内康三, 木上幸一郎, 二宮嘉正, 河野次郎, 鮫島哲郎, 川原岳, 後藤勇, 首藤謙二, 倉山茂樹, 中村純五, 岡原一徳, 三山吉夫]
通讯作者: 三山吉夫
A multicenter open label study to investigate the effect of a traditional Japanese medicine, yokukansan, on the behavioral and psychological symptoms of dementia in patients with Alzheimer's disease
一项多中心开放标签研究,旨在调查日本传统药物“抑肝散”对阿尔茨海默病患者痴呆行为和心理症状的影响
DOI: --
发表时间: 2009
期刊:
影响因子: --
作者: [Yoshihito Hayashi, Y Mitsuyama, Y Ishida]
通讯作者: Y Ishida
認知症患者の行動・心理症状(BPSD)に対する抑肝散長期投与の安産性および有効性の検討
检查长期服用 Yokukansan 对痴呆症患者行为和心理症状 (BPSD) 的安全给药和有效性
DOI: --
发表时间: 2012
期刊: Dementia Japan
影响因子: --
作者: [岡原一徳, 石田康, 林要人, 土屋利紀]
通讯作者: 土屋利紀
共 11 条
    The chemistry of lanthanide complexes with crown-ether type vanadate ligands
    • 批准号:
      23550069
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.91万
    • 财政年份:
      2011
    • 负责人:
      HAYASHI Yoshihito
    • 依托单位:
    Free radical production from betaAmyloid oligomers and mechanism of neurotoxicity deduced from them
    • 批准号:
      18591298
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.23万
    • 财政年份:
      2006
    • 负责人:
      HAYASHI Yoshihito
    • 依托单位:
    Construction reaction of bowl-type vanadium oxide molecule by template reaction
    • 批准号:
      16550051
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.14万
    • 财政年份:
      2004
    • 负责人:
      HAYASHI Yoshihito
    • 依托单位:
    Free -radical generation by amyloid p protein and the protective effect by laminin against amyloid β-protein induced toxicity
    海外基金